Abbreviations {#nomen0010}
=============

ABTS

:   2,2′-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid)

BSA

:   bovine serum albumin

CBF

:   cell-binding fragment

di-Trp

:   covalently cross-linked Trp residues

di-Tyr

:   the cross-linked species 3,3′-*o,o*-dityrosine

DTT

:   dithiothreitol

ECM

:   extracellular matrix

EDA

:   extra domain A

HCAEC

:   human coronary artery endothelial cells

HBF

:   heparin-binding fragment

HOCl

:   the physiological mixture of hypochlorous acid and its anion ^--^OCl

HOSCN

:   the physiological mixture of hypothiocyanous acid and its anion ^--^OSCN

HRP

:   horseradish peroxidase

mAb

:   monoclonal antibody

MMP

:   matrix metalloproteinase

MPO

:   myeloperoxidase

MTS

:   3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium

pAb

:   polyclonal antibody

PBS

:   phosphate-buffered saline

PBST

:   PBS with added Tween 20

TBST

:   Tris-buffered saline with added Tween 20

THF

:   tetrahydrofuran

TIMP

:   tissue inhibitor of MMPs

1. Introduction {#sec1}
===============

The heme enzyme myeloperoxidase (MPO) generates the potent oxidizing species hypochlorous acid (HOCl, the major active component of household bleach) at sites of inflammation using hydrogen peroxide (H~2~O~2~) and chloride ions (Cl^−^) (reviewed \[[@bib1]\]). This enzyme is released into the phagolysosomes of activated neutrophils, monocytes and some tissue macrophage-like cells, to kill invading pathogens \[[@bib2]\]; some MPO is also released extracellularly. This enzyme can also utilize other halide ions including bromide (Br^−^) and iodide (I^−^), and the pseudohalide thiocyanate (SCN^−^) to give hypobromous acid (HOBr), hypoiodous acid (HOI) and hypothiocyanous acid (HOSCN), respectively (reviewed \[[@bib1],[@bib3]\]). HOSCN can be formed to a significant extent under some conditions, due to the higher specificity constant of MPO for SCN^−^ compared to Cl^−^ \[[@bib4]\], and the high rate constant for HOSCN formation when compared to HOCl (rate constants, *k*, for reaction with MPO Compound I of 9.6 × 10^6^ and 2.5 × 10^4^ M^−1^ s^−1^ for SCN^−^ and Cl^−^, respectively \[[@bib5]\]). At neutral pH values HOCl is present as a near equal mixture of the neutral (HOCl) and ionized forms (^−^OCl), whereas HOSCN is predominantly present as the ionized anion ^−^OSCN (see Ref. \[[@bib1],[@bib3]\]). From here on, HOCl and HOSCN are used to describe these physiological mixtures.

HOCl formation by MPO is important in leukocyte-mediated pathogen clearance \[[@bib2]\]. However, the release of MPO extracellularly, due to aberrant processing, cell lysis, and neutrophil extracellular trap (NET) formation, can result in host tissue damage \[[@bib6], [@bib7], [@bib8], [@bib9]\]. This has been linked with many inflammatory diseases, and elevated levels of MPO-mediated biomarkers (e.g. 3-chlorotyrosine, from chlorination of the amino acid tyrosine, and chlorinated DNA bases) are associated with the severity of the pathology (reviewed \[[@bib1],[@bib3],[@bib10]\]).

HOCl can induce necrosis, apoptosis and other forms of cell death, and also modify extracellular targets, including plasma proteins and the extracellular matrix (ECM) (reviewed \[[@bib1]\]). Such damage appears to be particularly prevalent as extracellular compartments typically have much lower levels of antioxidant defenses and repair mechanisms \[[@bib11]\], and may be of particular significance as ECM proteins play a key role in defining tissue structure, bind materials such as lipoproteins and other proteins/enzymes \[[@bib12]\], and control key aspects of cell function, including adhesion, proliferation and metabolic activity \[[@bib13]\]. Many extracellular proteins are present at high concentration (e.g. 60--80 g protein L^−1^ for plasma) and have relatively long half-lives, such that they accumulate damage. Thus up to 70% of the damage detected in human artery atherosclerotic lesions has been reported to be present on ECM proteins \[[@bib14]\], including laminins, fibronectin and perlecan \[[@bib15], [@bib16], [@bib17], [@bib18], [@bib19], [@bib20]\]. Collagens (e.g. Type IV in basement membranes, and Types I and III in interstitial matrix \[[@bib21]\]) appear to be less important targets \[[@bib22]\], due to their low levels of HOCl-reactive side-chains. The damage induced by HOCl and MPO on fibronectin and laminins, has been examined by LC-MS protein mass mapping, with modifications detected at multiple sites \[[@bib17],[@bib18]\]. The uneven distribution of the observed modifications, the observed differences between reagent HOCl and the enzyme system, and also between proteins, has been suggested to arise from MPO binding, possibly via ionic interactions, to specific sites and proteins including fibronectin \[[@bib19],[@bib23], [@bib24], [@bib25]\].

Fibronectin is a key glycoprotein comprised of two near-identical monomers (220--270 kDa, dimer mass \~460 kDa) bound by two disulfide bonds at the carboxyl termini \[[@bib26],[@bib27]\]. The protein exists in two major isoforms: a soluble plasma form primarily synthesized and released by hepatocytes, and a less soluble cellular isoform synthesized by multiple cells including endothelial cells and fibroblasts \[[@bib28]\]. These forms differ primarily by the presence of extra domains (EDA and EDB) in the cellular form. Plasma fibronectin plays a key role in the coagulation cascade, via its interactions with fibrin, and in wound healing where it is a key component of the temporary ECM, and mediates cell adhesion \[[@bib28]\]. Basement membranes are a specialized ECM which underlies and supports endothelial and epithelial cells in most tissues. Cellular fibronectin is a key component of some basement membranes, including those of the vasculature, and is also found in some interstitial matrices. Fibronectin plays a key role in ECM assembly and function, including cell adhesion (by interacting with cell surface receptors and integrins) and proliferation \[[@bib26],[@bib28], [@bib29], [@bib30]\], and is particularly abundant in human atherosclerotic lesions \[[@bib26],[@bib27]\].

Although there is clear evidence for a role of HOCl in the modification of biological materials, including the ECM *in vivo*, less is known about the significance of SCN^−^, and HOSCN derived from it, in inflammatory pathologies. SCN^−^ may be of therapeutic value in reducing the extent of HOCl-induced damage, as HOSCN is a much less reactive and more selective oxidant \[[@bib31]\], and can be detoxified by intracellular antioxidant systems \[[@bib32]\]. SCN^−^ supplementation has been reported to be beneficial in animal models of cystic fibrosis, with evidence for decreased inflammation, pro-inflammatory cytokine levels, bacterial load and glutathione sulfonamide levels, a biomarker of HOCl production \[[@bib33],[@bib34]\]. Elevated levels of SCN^−^ have also been shown to decrease MPO-mediated damage to human plasma proteins \[[@bib35]\], modulate lesion formation in atherosclerosis-prone mice \[[@bib36],[@bib37]\] and rabbits \[[@bib38]\], and be associated with increased long-term survival in subjects who have suffered a first myocardial infarction \[[@bib39]\].

In the light of these data, we hypothesized that: 1) damage induced by a MPO/H~2~O~2~/Cl^−^ system on human plasma fibronectin would differ to that induced by MPO/H~2~O~2~/SCN^−^, due to differences in the chemistry of HOCl versus HOSCN, and also as a result of MPO binding to fibronectin, and 2) that damage generated by MPO/H~2~O~2~/Cl^−^ might be modulated by increasing SCN^−^ concentrations, due to a switch from HOCl to HOSCN generation. Decreased damage in the presence of SCN^−^, could therefore rationalize the positive effects of high levels of SCN^−^ detected in the pathologies described above.

2. Materials and methods {#sec2}
========================

2.1. Materials {#sec2.1}
--------------

Chemicals and reagents were from Sigma Aldrich/Merck (Castle Hill, NSW, Australia; Søborg, Denmark) unless stated otherwise. The water used to prepare solutions was filtered through a four-stage Millipore MilliQ system ("MilliQ water"), with Chelex resin used to remove trace metal ions. Phosphate-buffered saline (PBS, 20x stock), sodium carbonate, Tris, and 37% (w/v) formaldehyde were purchased from Amresco (Solon, OH, USA). Sodium chloride was from UNIVAR (Redmond, Washington, USA). Human polymorphonuclear leukocyte-derived MPO was purchased from Planta Natural Products (Vienna, Austria). NuPAGE 3--8% w/v Tris-acetate gels, NuPAGE Tris-acetate SDS Running buffer (20x stock; LA0041), HiMark™ pre-stained and unstained high molecular mass standards, iBlot 2, and polyvinylidene difluoride (PVDF) membrane transfer stacks were from Life Technologies (Slangerup, Denmark). Western Lightning Plus-Electrochemiluminescence reagent for detection of proteins on immunoblots was obtained from PerkinElmer (Waltham, MA, USA). The antibodies used were: a mouse monoclonal antibody (mAb) against the fibronectin cell-binding fragment (CBF) (clone A17; Abcam, Cambridge, UK), a mouse mAb against the heparin-binding fragment (HBF; clone A32; Rockford, USA), a mouse mAb against the extra domain A (EDA) splice variant (clone 3E2, Sigma, Denmark), a mouse mAb (clone 2D10G9) raised against HOCl-modified epitopes (kindly provided by Prof. Ernst Malle, Medical University of Graz, Austria) \[[@bib40]\], and a polyclonal rabbit anti-fibronectin antibody (pAb) (ab2413; Abcam, Cambridge, UK). CellTiter 96 ® Aqueous One Solution Assay for cellular metabolic activity measurements was obtained from Promega (Wisconsin, USA).

2.2. ELISA {#sec2.2}
----------

High-binding 96-well plates were coated with purified human plasma (50 μL, 0.02 μM) overnight at 4 ᵒC, and then washed twice with PBS. Our previous studies indicate that under these conditions \~96% of the fibronectin adheres to the plates \[[@bib16]\]. For oxidant treatment, the wells were incubated with 0.02 μM of MPO (i.e. equimolar with the fibronectin concentration), 100 mM Cl^−^, variable concentrations of SCN^−^ (0--500 μM) and lastly 32 μM H~2~O~2~ (added as 4 aliquots of 8 μM) in a total volume of 50 μL, for 2 h at 37 ᵒC. The samples were washed twice with PBS to remove any residual oxidant, and subsequently blocked with 0.1% (w/v) casein in PBS for 1 h at 21 ᵒC on a rocking platform. The wells were then washed twice with PBS containing Tween 20 (PBST, 0.01% (v/v)) and probed using the antibodies against the CBF (A17, 1:10000), HBF (A32, 1:2000), EDA (3E2, 1:1000) and HOCl-generated epitopes (2D10G9, 1:100) by incubation with the primary antibodies diluted in 0.1% (w/v) casein in PBS overnight at 4 ᵒC. The wells were washed twice with PBST, prior to incubation with a secondary rabbit anti-mouse antibody conjugated with alkaline phosphatase (1:1000, Abcam) and *p*-nitrophenylphosphate solution (Merck) at 21 °C for 20 min. The optical absorbance of the resulting *p*-nitrophenolate anion was determined using a Spectra Max i3x microplate reader (Molecular Devices). The alkaline phosphatase system was used, rather than HRP/ABTS/H~2~O~2~, as both HRP and MPO can react with H~2~O~2~ potentially resulting in erroneous absorbance values (cf \[[@bib19]\]).

2.3. SDS-PAGE, silver staining and immunoblotting {#sec2.3}
-------------------------------------------------

Purified human plasma fibronectin (0.2 μM in 0.1 M phosphate buffer, pH 7.4) was left untreated (control), treated with 0.02 or 0.1 μM MPO/100 mM Cl^−^ and increasing concentrations of H~2~O~2~ (0, 20, 40, 80, 120, 160 μM, added in aliquots as described above) and incubated for 2 h at 37 °C. Alternatively, fibronectin (as above) was treated with 0.2 μM MPO, 20 or 500 μM SCN^−^ and increasing concentrations of H~2~O~2~ (0, 20, 40, 80, 120, 160 μM), and incubated for 2 h at 37 °C. Samples were prepared for analysis by addition of NuPAGE® LDS Sample Buffer (4x stock), in the absence or presence of NuPAGE® Sample Reducing Buffer (10x stock) following the manufacturer\'s instructions, and denatured for 10 min at 70 ᵒC. Aliquots were then loaded onto 1 mm NOVEX® 3--8% Tris-Acetate Gels (0.25--1.25 μg protein per well) with Tris-Acetate SDS Running buffer, and run at 160 V at a constant current for 70 min. Gels were subsequently developed using silver staining \[[@bib41]\], or immunoblotted to PVDF membranes to examine the presence of functional or damaged epitopes.

For the immunoblotting analyses, proteins were transferred to PVDF membranes using an iBlot 2® Gel Transfer device (Life Technologies), and blocked using 1% (w/v) BSA in TBST for 1 h followed by incubation with primary antibodies (overnight, 4 ᵒC) at the dilutions given above. The membranes were then washed with TBST for 5 min before incubation with a secondary HRP-conjugated sheep anti-mouse IgG antibody (1:5000, 1 h, 21 ᵒC). The membranes were then washed and chemiluminescence recorded using either a Bio-rad Chemidoc™ or a Syngene G:Box XR5 system.

2.4. Cell culture {#sec2.4}
-----------------

Human coronary artery endothelial cells (HCAEC, from 3 independent donors; Cell Applications, San Diego, CA, USA) were cultured using MesoEndo Endothelial Cell Growth Media (Cell Applications) and used at passages 4--6. HCAEC were removed from the culture plates by treatment with 0.1% (w/v) trypsin-EDTA for 1 min at 37 °C before deactivation of trypsin with added growth media. The cells were then pelleted by centrifugation (5 min, \~232 *g*), the supernatant removed by aspiration, and the cells resuspended in media before seeding overnight at a density of 2 × 10^5^ cells mL^−1^.

2.5. Cell adhesion and metabolic activity assays {#sec2.5}
------------------------------------------------

Tissue culture plates (clear bottom, 96-wells) were coated with purified human plasma fibronectin (0.02 μM) as described above. The bound protein was exposed to the different oxidation systems (as above) for 2 h at 37ᵒC, and then washed twice with PBS. The wells were blocked to minimize non-specific binding using 3% (w/v) BSA in PBS (1 h, 37 ᵒC), and subsequently washed twice with sterile PBS. HCAEC (2.0 × 10^5^ cells mL^−1^) were pre-loaded with 5 μM calcein-AM for 30 min at 37 °C, with residual probe removed by washing with pre-warmed medium (Cell Applications). Calcein-AM loaded cells (12500 per well) were added and incubated in a tissue culture incubator at 37 °C for 90 min. The plates were then rinsed twice with sterile PBS (containing Ca^2+^ and Mg^2+^) to remove non-adherent cells, and fluorescence arising from cleavage (by intracellular esterases of viable cells) of the non-fluorescent parent to the fluorescent product, recorded using a SpectraMax® i3x microplate reader with *λ*~ex~ 490 nm and *λ*~em~ 520 nm. Cellular metabolic activity was examined using the reduction of 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS assay) as described previously \[[@bib16]\].

2.6. Statistics {#sec2.6}
---------------

GraphPad Prism was used for statistical analysis (version 6.07; GraphPad Software, San Diego, CA, USA). One-way ANOVA with Tukey\'s multiple comparison test was used to determine statistical differences, at the p \< 0.05 level.

3. Results {#sec3}
==========

3.1. Effects of MPO/H~2~O~2~/Cl^−^ and MPO/H~2~O~2~/SCN^−^ on human plasma fibronectin detected by ELISA {#sec3.1}
--------------------------------------------------------------------------------------------------------

Human plasma fibronectin (0.02 μM) was exposed to MPO/H~2~O~2~/Cl^−^ and MPO/H~2~O~2~/SCN^−^ systems using both low (0.02 μM) and high (0.1 μM) concentrations of MPO to reflect a non-diseased and diseased state. Under the former conditions the molar ratio of MPO to fibronectin is 1:1, allowing stoichiometric binding \[[@bib19]\] with an assumed single high affinity binding site. With the higher MPO concentration, binding to the fibronectin may occur at multiple sites, or result in non-bound enzyme being present. A range of H~2~O~2~ concentrations were examined (0, 20, 40, 80, 120, 160 μM). Physiological concentrations of Cl^−^ (100 mM) were used in the MPO/H~2~O~2~/Cl^−^ system, and either 20 μM or 500 μM SCN^−^ for the MPO/H~2~O~2~/SCN^−^ system. These two concentrations span the range of SCN^−^ detected in human plasma \[[@bib36],[@bib38],[@bib42],[@bib43]\]. Structural modifications to the fibronectin protein were analyzed by ELISA, or by silver staining or immunoblotting, after protein separation by SDS-PAGE.

Incubation of human plasma fibronectin with MPO/H~2~O~2~/Cl^−^ resulted in a statistically-significant loss of recognition of the CBF epitope starting at an 800x molar excess of H~2~O~2~, with this occurring in a dose-dependent manner ([Fig. 1](#fig1){ref-type="fig"}A). A \~35% loss of epitope recognition was detected with the 1600x molar excess of H~2~O~2~ ([Fig. 1](#fig1){ref-type="fig"}A). No significant changes were detected with H~2~O~2~ alone (data not shown). Examination of the recognition of the HBF epitope showed a similar dose-dependent loss of recognition with a statistically-significant loss observed with the 800x molar excess of H~2~O~2~ and \~50% with the 1600x molar excess of H~2~O~2~ ([Fig. 1](#fig1){ref-type="fig"}B)^.^ Modifications to these epitopes were accompanied by a dose-dependent increase in epitopes recognized by mAb 2D10G9, an antibody raised against HOCl-damaged proteins ([Fig. 1](#fig1){ref-type="fig"}C). A statistically-significant increase in this material was detected with a 800x molar excess of H~2~O~2~, and further increases were detected with increasing H~2~O~2~ concentrations ([Fig. 1](#fig1){ref-type="fig"}C). These ELISA data mirror those observed with reagent HOCl \[[@bib16]\].Fig. 1ELISA of human plasma FN modified using enzymatic treatment with MPO/Cl^−^ or MPO/SCN^−^ in the presence of H~2~O~2~. Each well was coated with 0.5 μg (0.02 μM of FN in 0.1 M phosphate buffer, pH 7.4) and either left untreated (0 μM H~2~O~2~) or treated with 0.02 μM MPO/Cl^−^, 0.02 μM MPO/20 or 500 μM SCN^−^, 0.02 μM MPO/Cl^−^/0--500 μM SCN^−^ and increasing concentrations of H~2~O~2~ (0, 4, 8, 16, 24, 32 μM), incubated for 2 h at 37 °C. FN epitopes were detected using a mouse monoclonal anti-FN CBF antibody (A17; 1:10000), anti-FN HBF antibody (A32; 1:1000), anti-HOCl generated epitope (2D10G9; 1:50), and conjugated with anti-mouse AP secondary (1:1000). The data are presented as a percentage relative to control (0 μM H~2~O~2~). Error bars are ±SD from three technical replicates obtained from each of three independent experiments. Statistical analysis was performed using one-way ANOVA with Tukey\'s multiple comparison post hoc tests to determine significance. Statistical significance is identified as follows: \*\* = p \< 0.01, \*\*\* = p \< 0.001, and \*\*\*\* = p \< 0.0001.Fig. 1

Similar ELISA experiments were carried out with a MPO/SCN^−^/H~2~O~2~ system using either 20 μM or 500 μM of SCN^−^ and identical concentrations of MPO and H~2~O~2~. Exposure of the fibronectin to 0.02 μM MPO with 20 μM of SCN^−^, and up to a 1600x molar excess of H~2~O~2~, did not give any significant changes in CBF epitope recognition ([Fig. 1](#fig1){ref-type="fig"}D). However, with 500 μM SCN^−^ and increasing concentrations of H~2~O~2~ above a 400x molar excess, there was a statistically-significant increase in epitope recognition. This increase was sustained at higher H~2~O~2~ concentrations ([Fig. 1](#fig1){ref-type="fig"}E). Studies of the fibronectin HBF epitope, using 20 μM SCN^−^ and increasing concentrations of H~2~O~2~, provided no evidence for modifications to this epitope ([Fig. 1](#fig1){ref-type="fig"}F). With 500 μM SCN^−^, and increasing molar excesses of H~2~O~2~, a small but significant increase in recognition of the HBF epitope was detected with a 400x molar excess of H~2~O~2~ ([Fig. 1](#fig1){ref-type="fig"}G), but with higher H~2~O~2~ concentrations (800x molar excess and up) this effect was reversed, and a significant loss of HBF epitope recognition was observed ([Fig. 1](#fig1){ref-type="fig"}G).

3.2. Effects of MPO/H~2~O~2~/Cl^−^ and MPO/H~2~O~2~/SCN^−^ on human plasma fibronectin detected by SDS-PAGE with silver staining {#sec3.2}
--------------------------------------------------------------------------------------------------------------------------------

Fibronectin samples treated with an MPO enzymatic system with either 0.02 μM or 0.1 μM of MPO, 100 mM of Cl^−^, and increasing concentrations of H~2~O~2~ (0, 20, 40, 80, 120, 160 μM), were analyzed by SDS-PAGE with silver staining ([Fig. 2](#fig2){ref-type="fig"}). As expected, for the untreated controls both the parent dimer (\~440 kDa) and monomer (broad band at \~ 220 kDa with the two chains unresolved) were detected under non-reducing conditions, and only the monomer under reducing conditions, due to cleavage of the two inter-chain disulfide bonds. For enzyme treated samples, formation of dimers and higher aggregates (black arrow) were observed with both MPO concentrations, and under both non-reducing and reducing conditions. Increasing levels of aggregates were detected with increasing H~2~O~2~ concentrations, and the bands became more diffuse (smeared) at the highest oxidant levels, indicative of a heterogeneity in the species present. Concurrent with this, and with the higher concentration of MPO, a loss of the parent dimer (under non-reducing conditions, black arrow) and the monomer band (under both conditions, white arrow) were detected ([Fig. 2](#fig2){ref-type="fig"}). Bands assigned to species with altered structures were also detected, with both MPO concentrations, above and below the parent monomer, with higher oxidant exposure ([Fig. 2](#fig2){ref-type="fig"}). In addition, a shift in the apparent molecular mass of the dimer was detected in the presence of H~2~O~2~ compared to its absence (cf. the first two lanes in [Fig. 2](#fig2){ref-type="fig"}A). With the higher concentration of MPO, a prominent band was also detected at \~130 kDa, possibly from a fragment species; this was not detected with the lower concentration of MPO, or under reducing conditions.Fig. 2Silver staining of SDS-PAGE gels indicates structural changes to human plasma FN treated with MPO/H~2~O~2~/Cl^−^ or MPO/H~2~O~2~/SCN^−^. Purified human plasma FN (0.2 μM in 0.1 M phosphate buffer, pH 7.4) was left untreated (control 0x H~2~O~2~), treated with 0.02 or 0.1 μM MPO/Cl^−^ (A, B) or treated with 0.2 μM MPO/20 or 500 μM SCN^−^ (C, D) and increasing concentrations of H~2~O~2~ (0, 20, 40, 80, 120, 160 μM), and incubated for 2 h at 37 °C. Samples were electrophoresed on 3--8% Tris-acetate SDS-PAGE gels under non-reducing (A, C) or reducing conditions (B, D). Gels were then fixed, and visualized with silver staining and referenced against HiMark™ pre-stained High Molecular Mass standards. Data are labelled as follows: black arrow = dimer/higher aggregates, and white arrow = monomer bands.Fig. 2

For the samples run under reducing conditions, increasing concentrations of non-reducible dimers were detected with increasing concentrations of H~2~O~2~ ([Fig. 2](#fig2){ref-type="fig"}B), with this being particularly notable with the low MPO concentration. These species were less apparent with the higher MPO concentration (0.1 μM), but an increased amount of material was detected at the top of the gel, with high levels of H~2~O~2~, consistent with the presence of very high mass species, possibly formed by further reaction of initial oligomers ([Fig. 2](#fig2){ref-type="fig"}B). An increased abundance of species with altered mobility/structure was also detected with the 0.02 μM MPO treatment, just above the parent monomer band ([Fig. 2](#fig2){ref-type="fig"}B). These data suggest that the extent and/or types of modifications are dependent on the MPO concentration.

For the corresponding MPO/H~2~O~2~/SCN^−^ system, experiments were only carried out with the lower level of MPO (0.02 μM) and 0.02 μM fibronectin, but with either 20 μM or 500 μM of SCN^−^, and increasing concentrations of H~2~O~2~. Under non-reducing conditions, with 20 μM SCN^−^, increasing concentrations of H~2~O~2~ resulted in changes to the protein structure ([Fig. 2](#fig2){ref-type="fig"}C). With a 200-fold molar excess of H~2~O~2~, additional bands were detected above and below the dimer band at \~440 kDa. Higher mass bands (\>460 kDa) decreased in intensity above a 400-fold excess of H~2~O~2~, whilst those with masses between 220 and 440 kDa were detected over the entire H~2~O~2~ concentration range examined ([Fig. 2](#fig2){ref-type="fig"}C). A prominent fragment was also detected at \~130 kDa, with the detection of this species being dependent on the presence and concentration of H~2~O~2~ ([Fig. 2](#fig2){ref-type="fig"}C). With 500 μM SCN^−^, the species observed at masses above and below the dimer, with 20 μM SCN^−^, were also detected, but the band at \~130 kDa was not observed ([Fig. 2](#fig2){ref-type="fig"}C). In addition, increased staining was detected at the top of the gels, and in the loading wells, with 200--800x molar excesses of H~2~O~2~ consistent with the presence of high mass aggregates ([Fig. 2](#fig2){ref-type="fig"}C). Under reducing conditions, less marked changes were detected, but low levels of non-reducible (covalent) cross-links were detected at \~440 kDa with increasing H~2~O~2~ exposure, and higher levels of very high mass aggregates were detected near, and at, the top of the gels with high levels of H~2~O~2~ ([Fig. 2](#fig2){ref-type="fig"}D).

3.3. Effects of the MPO/H~2~O~2~/Cl^−^ and MPO/H~2~O~2~/SCN^−^ systems on human plasma fibronectin detected by SDS-PAGE with immunoblotting {#sec3.3}
-------------------------------------------------------------------------------------------------------------------------------------------

Immunoblotting was used to examine potential changes to the CBF and HBF epitopes, using the same reactions systems described above. Immunoblots from non-reducing gels, probed with an anti-CBF mAb, showed a loss of antibody recognition in a H~2~O~2~ dose-dependent manner, with a marked loss observed with both MPO concentrations, and particularly 0.1 μM MPO, and 100--800x molar excesses of H~2~O~2~, with an appreciable loss in intensity of both the monomer (white arrow) and dimer (black arrow) bands ([Fig. 3](#fig3){ref-type="fig"}A). No significant changes were detected with H~2~O~2~ alone (data not shown). Aggregate formation was observed with both MPO concentrations, and particularly 0.02 μM MPO, with lower levels detected with the high MPO concentration ([Fig. 3](#fig3){ref-type="fig"}A). Under reducing conditions, the loss of the monomer band immunoreactivity was less noticeable with both MPO concentrations, but a notable formation of covalent (non-reducible) dimers with apparent masses \> 460 kDa, were detected with both MPO concentrations, and particularly low MPO levels. These data are consistent with different behavior of the two MPO concentrations ([Fig. 3](#fig3){ref-type="fig"}B). Similar experiments with the HBF mAb yielded a similar pattern of changes with blots run under both non-reducing and reducing conditions ([Fig. 3](#fig3){ref-type="fig"}C and D respectively), with formation of species with altered gel mobility, generation of reducible and non-reducible dimers and aggregates, and a loss of parent protein recognition, particularly with the higher concentration of MPO and high H~2~O~2~. Experiments were not carried out with mAb 2D10G9, as this antibody does not work effectively in immunoblotting \[[@bib16]\].Fig. 3Immunoblots of structural changes to human plasma fibronectin treated with MPO/H~2~O~2~/Cl^−^. Samples were separated on SDS-PAGE under non-reducing (A, C) or reducing (B, D) conditions as described in the legend to [Fig. 2](#fig2){ref-type="fig"}, and then transferred onto PVDF membranes and probed with mouse monoclonal anti-FN CBF antibody (A, B; A17; 1:10000) or anti-FN HBF antibody (C, D; A32; 1:2000), followed by anti-mouse HRP-conjugated secondary antibody (1:2000). Blots were developed with chemiluminescence reagent and data labelled as follows: black arrow = dimer/higher aggregates, and white arrow = monomer bands.Fig. 3

Analogous experiments were carried out with the MPO/SCN^−^/H~2~O~2~ system (as above). The changes detected to the fibronectin CBF under non-reducing conditions were similar to those detected at the protein level by silver staining ([Fig. 2](#fig2){ref-type="fig"}A), though more pronounced. With 20 μM SCN^−^, and H~2~O~2~ molar excesses ≥200, a significant loss of antibody recognition of both the parent dimer and monomer bands were detected, which was dose-dependent with higher H~2~O~2~ concentrations ([Fig. 4](#fig4){ref-type="fig"}A). In addition, formation of a prominent fragments, containing the CBF domain, with an apparent molecular mass of 300--350 kDa (i.e. between the parent dimer and monomer bands) was observed ([Fig. 4](#fig4){ref-type="fig"}A). With 500 μM SCN^−^ a similar, but less marked (when compared to 20 μM SCN^−^) loss of recognition of the parent dimer and monomer bands was detected ([Fig. 4](#fig4){ref-type="fig"}A). Fragmentation to give the 300--350 kDa species was also detected but to a lesser extent ([Fig. 4](#fig4){ref-type="fig"}A). Under reducing conditions, a minor loss of anti-CBF recognition against the parent monomer band was detected with both concentrations of SCN^−^ ([Fig. 4](#fig4){ref-type="fig"}B), the 300--350 kDa fragment was not observed, but low levels of dimers with a mass of \~460 kDa were detected with increasing H~2~O~2~ concentrations ([Fig. 4](#fig4){ref-type="fig"}B). The anti-HBF antibody gave a similar pattern of data ([Fig. 4](#fig4){ref-type="fig"}C and D). For gels run under non-reducing conditions, with both 20 μM and 500 μM SCN^−^, a dose-dependent loss of recognition of both the parent dimer and monomer bands were detected with 200--800x molar excesses of H~2~O~2~ ([Fig. 4](#fig4){ref-type="fig"}C), and the fragment species at 300--350 kDa was detected with a 200x molar excess, or higher, of H~2~O~2~; this fragment was less prominent at higher SCN^−^ concentration ([Fig. 4](#fig4){ref-type="fig"}C). For the samples electrophoresed under reducing conditions less marked changes were detected, though with 20 μM SCN^−^, an increased recognition of the HBF was detected with increasing concentrations of H~2~O~2~ ([Fig. 4](#fig4){ref-type="fig"}D). This was less apparent with 500 μM SCN^−^ ([Fig. 4](#fig4){ref-type="fig"}D). Neither fragmentation nor crosslink formation was observed for either low or high concentrations of SCN^−^ under reducing conditions ([Fig. 4](#fig4){ref-type="fig"}D).Fig. 4Immunoblots of structural changes to human plasma FN treated with MPO/H~2~O~2~/SCN^−^. Human plasma FN was separated using SDS-PAGE under non-reducing (A, C) or reducing (B, D) conditions, and then transferred onto PVDF membranes and probed with either the mouse monoclonal anti-FN CBF antibody (A, B; A17; 1:10000) or anti-FN HBF antibody (C, D; A32; 1:2000), followed by HRP conjugated anti-mouse HRP secondary antibody (1:2000). Blots were developed with chemiluminescence reagent and data labelled as follows: black arrow = dimer/higher aggregates, and white arrow = monomer band.Fig. 4

In light of these data indicating modifications to the biologically important CBF of fibronectin, experiments were performed to quantify human coronary artery endothelial cell (HCAEC) adhesion and metabolic activity on exposure to modified fibronectin.

3.4. Effects of the MPO/H~2~O~2~/Cl^−^ and MPO/H~2~O~2~/SCN^−^ induced modification on human plasma fibronectin on primary human coronary artery endothelial cell (HCAEC) adhesion and metabolic activity {#sec3.4}
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Surface-bound human plasma fibronectin (0.02 μM) was left untreated (control) or treated with the MPO/H~2~O~2~/Cl^−^ system using either 400- or 1600-fold molar excesses of H~2~O~2~; the full range of H~2~O~2~ concentrations used in the SDS-PAGE and immunoblotting studies were not employed due to the low availability of primary human cells. Fibronectin that had been oxidant-treated was washed twice to remove excess oxidant before addition of the cells, thereby preventing direct cell-oxidant interactions. Pre-treatment of fibronectin with MPO/H~2~O~2~/Cl^−^, with increasing concentrations of H~2~O~2~, prior to cell addition resulted in a statistically-significant (\~30%) loss of HCAEC adhesion with a 1600x molar excess of H~2~O~2~, when compared to untreated controls (0x H~2~O~2~ molar excess; [Fig. 5](#fig5){ref-type="fig"}A). As cells may remain attached to a sub-strata, but have reduced metabolic activity, studies were also carried out to assess functional activity on exposure to modified fibronectin. Thus, HCAEC adherent on native and modified fibronectin (as above) were subsequently incubated in growth media for a further 48 h. MTS reagent was then added, and reduction of MTS to formazan by cellular NAD(P)H dehydrogenase enzymes was quantified. Cells incubated on fibronectin pre-treated with MPO/H~2~O~2~/Cl^−^ using a 400x or 1600x molar excess of H~2~O~2~, showed a statistically-significant decrease in metabolic activity ([Fig. 5](#fig5){ref-type="fig"}D). The corresponding MPO/H~2~O~2~/SCN^−^system with either 20 μM or 500 μM SCN^−^, and a 400x or 1600x molar excesses of H~2~O~2~, did not give any statistically-significant differences in HCAEC adhesion ([Fig. 5](#fig5){ref-type="fig"}B and C) or metabolic activity ([Fig. 5](#fig5){ref-type="fig"}E and F). In light of these differences between the MPO/H~2~O~2~/Cl^−^ and MPO/H~2~O~2~/SCN^−^ systems, investigations were conducted with a MPO/H~2~O~2~/Cl^−^/SCN^−^ systems with Cl^−^ and SCN^−^ present simultaneously but at different ratios.Fig. 5Calcein-AM fluorescence and proliferation of HCAEC incubated on human plasma FN treated with MPO/H~2~O~2~/Cl^−^ or MPO/H~2~O~2~/SCN^−^. Surface-bound human plasma FN (0.02 μM) was left untreated (0x H~2~O~2~), treated with MPO/Cl^−^ (A, D), MPO/20 μM SCN^−^ (B, E) or MPO/500 μM SCN^−^ (C, F), and increasing concentration of H~2~O~2~ (0, 8, 32 μM) and incubated for 2 h at 37 °C before incubation with HCAEC pre-stained with calcein-AM and subsequent detection of fluorescence to quantify cell adhesion (A, B, C). Plates were then washed prior to addition of growth media and HCAEC were left to recover over 48 h. MTS reagent was added into each well and absorbance was measured at 490 nm after 3 h for cell proliferation assay (D, E, F). All data are presented as a percentage of the control, with no added H~2~O~2~. Error bars are ±SD from three technical replicates obtained from each of three independent experiments. Statistical analysis was performed using one-way ANOVA with Tukey\'s multiple comparison post hoc tests to determine significance. Statistical significance is identified as follow: \* = p \< 0.05.Fig. 5

3.5. Effects of MPO/H~2~O~2~/Cl^−^ systems in the presence of increasing concentrations of SCN^−^on functional epitopes of human plasma fibronectin detected by ELISA {#sec3.5}
---------------------------------------------------------------------------------------------------------------------------------------------------------------------

Surface-bound human plasma fibronectin (0.02 μM) was incubated with MPO (0.02 μM), Cl^−^ (100 mM), SCN^−^ (0--500 μM) and H~2~O~2~ (32 μM, i.e. 1600-fold molar excess, added last) for 2 h at 37 °C. The wells were then washed before analysis by ELISA for CBF and HBF epitopes, and material recognized by mAb 2D10G9. Treatment in the absence of added SCN^−^ resulted in a significant loss in recognition of the CBF and HBF epitopes, and a significant increase in material recognized by 2D10G9 ([Fig. 1](#fig1){ref-type="fig"}H--J, cf. [Fig. 1](#fig1){ref-type="fig"}A--C). However, the presence of 20 μM or higher SCN^−^ reversed these changes, with the absorbance values restored to control levels ([Fig. 1](#fig1){ref-type="fig"}H--J).

3.6. Effects of MPO/H~2~O~2~/Cl^−^ with increasing concentrations of SCN^−^ on functional epitopes of human plasma fibronectin detected by SDS-PAGE-silver staining and immunoblotting {#sec3.6}
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The effects of increasing SCN^−^ on the structural changes induced by the MPO/H~2~O~2~/Cl^−^ system were examined by SDS-PAGE with silver staining, and also by immunoblotting. Purified human plasma fibronectin (0.02 μM) was either left unoxidized (MPO only control) or treated with MPO (0.02 or 0.1 μM), Cl^−^ (100 mM), SCN^−^ (0--500 μM) and H~2~O~2~ (160 μM, added last). Samples were then separated on SDS-PAGE prior to silver staining or immunoblotting. Under non-reducing conditions, the fibronectin monomer bands (white arrow) were decreased in staining intensity by MPO/H~2~O~2~/Cl^−^ treatment in the absence of SCN^−^ ([Fig. 6](#fig6){ref-type="fig"}A). This treatment also induced fragmentation, with additional bands detected at lower molecular masses, and aggregates at higher molecular mass. In the presence of 20 μM SCN^−^, fewer higher mass aggregates were detected, but greater staining intensity between 260 and 460 kDa, suggesting that these phenomena are linked ([Fig. 6](#fig6){ref-type="fig"}A). Additional fragments with masses \<190 kDa were more prominent with increasing concentrations of SCN^−^ ([Fig. 6](#fig6){ref-type="fig"}A). With high concentrations of SCN^−^ (400 and 500 μM), fewer bands were detected in the 260--460 kDa range, and the intensity of the lower mass fragments was reduced. Experiments carried out with 0.1 μM MPO under non-reducing conditions, gave similar modifications to those seen with 0.02 μM MPO, together with greater loss of the parent dimer (black arrow) and monomer bands (white arrow) ([Fig. 6](#fig6){ref-type="fig"}A). In the presence of 500 μM SCN^−^, the modifications detected were similar to those detected with the MPO/H~2~O~2~/SCN^−^ system ([Fig. 2](#fig2){ref-type="fig"}C), and pre-formed HOSCN \[[@bib16]\].Fig. 6Silver staining of SDS-PAGE gels showing structural changes to human plasma FN treated with MPO/H~2~O~2~/Cl^−^ in the presence of increasing concentrations of SCN^−^. Purified human plasma FN (0.2 μM in 0.1 M phosphate buffer, pH 7.4) was either left untreated (MPO only control) or treated with MPO/H~2~O~2~/Cl^−^ and the indicated concentrations of SCN^−^ for 2 h at 37 °C. Samples were electrophoresed using 3--8% Tris-acetate SDS-PAGE gels under: A) non-reducing, or B) reducing conditions. Gels were then fixed, and visualized with silver staining and referenced against HiMark™ pre-stained high molecular mass standards. Black arrow = dimer/higher aggregates; white arrow = monomer bands.Fig. 6

Similar samples run under reducing conditions, indicated the presence of the fibronectin monomer and fragments in the absence of SCN^−^ with both MPO concentrations ([Fig. 6](#fig6){ref-type="fig"}B). These species were also detected in the presence of SCN^−^ at concentrations up to 100 μM, but at higher SCN^−^ concentrations these species were less prevalent and almost completely absent at the highest concentrations ([Fig. 6](#fig6){ref-type="fig"}B). With the higher SCN^−^ concentrations, low levels of non-reducible dimers were detected together with some smearing of the monomer band to higher apparent masses ([Fig. 6](#fig6){ref-type="fig"}B).

Immunoblotting for the CBF and HBF epitopes was also employed, as described above. Under non-reducing conditions, use of the anti-CBF antibody, in the absence of SCN^−^, showed the presence of extensive aggregation and fragmentation, together with a loss of the parent monomer (white arrow) and dimer bands (black arrow) ([Fig. 7](#fig7){ref-type="fig"}A; cf. [Fig. 3](#fig3){ref-type="fig"}). In the presence of added SCN^−^ (20 μM) several specific fragments were detected, with masses between those of the dimer and monomer ([Fig. 7](#fig7){ref-type="fig"}A). Increases in the SCN^−^ concentration led to a decrease in HOCl-induced modifications, with the detection of fragments and aggregates similar to those seen with the MPO/H~2~O~2~/SCN^−^ system with no Cl^−^ (cf. [Fig. 4](#fig4){ref-type="fig"}A). Of particular note is the recovery of recognition of the parent fibronectin band with high SCN^−^ levels, consistent with decreased modification of the parent protein, though the appearance of two discreet bands suggests two populations of the dimeric protein are present. Similar, but more marked effects were detected in experiments carried out using 0.1 μM MPO.Fig. 7Immunoblotting for CBF showing structural changes to human plasma FN treated with a MPO/H~2~O~2~/Cl^−^ system in the presence of increasing concentrations of SCN^−^. Purified human plasma FN (0.2 μM in 0.1 M phosphate buffer, pH 7.4) was either left untreated (MPO only control) or treated with MPO (0.02 or 0.1 μM), Cl^−^ (100 mM), H~2~O~2~ (160 μM) and increasing concentration of SCN^−^, and incubated for 2 h at 37 °C. Samples were electrophoresed on SDS-PAGE under A) non-reducing or B) reducing conditions, transferred onto PVDF membranes and probed with a mouse monoclonal anti-FN CBF antibody (A17; 1:10000), and conjugated with anti-mouse HRP secondary antibody (1:2000). Blots were developed with ECL-plus reagent. Black arrow = dimer/higher aggregates; white arrow = monomer bands.Fig. 7

Analogous experiments carried out under reducing conditions ([Fig. 7](#fig7){ref-type="fig"}B), yielded data indicating that increasing concentrations of SCN^−^ decrease the extent of modification induced by MPO-generated HOCl. Thus, with both concentrations of MPO, in the presence of H~2~O~2~ and Cl^−^, significant formation of both non-reducible (covalent) dimers and also fragments were detected. However, the presence of increasing concentrations of SCN^−^ decreased this damage, such that with the highest levels of SCN^−^, HOCl-mediated modification was almost completely abrogated ([Fig. 7](#fig7){ref-type="fig"}B). Similar behavior was detected for both the non-reducing and reducing system when the membranes were probed with the anti-HBF antibody ([Fig. 8](#fig8){ref-type="fig"}A and B).Fig. 8Immunoblotting for HBF showing structural changes to human plasma FN treated with a MPO/H~2~O~2~/Cl^−^ system and increasing concentrations of SCN^−^. Purified human plasma FN (0.2 μM in 0.1 M phosphate buffer, pH 7.4) was either left untreated (MPO only control) or treated with MPO (0.02 or 0.1 μM), Cl^−^ (100 mM), H~2~O~2~ (160 μM) and increasing concentration of SCN^−^, and incubated for 2 h at 37 °C. Samples were electrophoresed on SDS-PAGE under A) non-reducing or B) reducing conditions, transferred onto PVDF membranes and probed with a mouse monoclonal anti-FN HBF antibody (A32; 1:5000), and conjugated with anti-mouse HRP secondary antibody (1:2000). Blots were developed with ECL-plus reagent. Black arrow = dimer/higher aggregates; white arrow = monomer band.Fig. 8

4. Discussion {#sec4}
=============

The experiments reported here indicate the exposure of fibronectin to an enzymatic MPO/H~2~O~2~/Cl^−^ system results in damage to the functionally important CBF and HBF domains and gross structural changes to the protein. These changes result in altered adhesion and metabolic activity of naïve HCAEC exposed to this pre-oxidized fibronectin. Significant differences were observed between the effects of stoichiometric, and above-stoichiometric, MPO relative to the fibronectin concentration, consistent with stoichiometric binding of MPO to fibronectin. In contrast, the MPO/H~2~O~2~/SCN^−^ system induced limited changes, with no damage detected to the CBF and HBF domains, less protein modification, and no effects on HCAEC adhesion or metabolic activity. Addition of increasing SCN^−^ to the MPO/H~2~O~2~/Cl^−^ system, to provide competition for the key MPO catalytic intermediate and therefore decrease HOCl formation, afforded protection, with \>20 μM SCN^−^ decreasing damage to the functional domains and protein structure, and maintaining native HCAEC behavior.

High plasma MPO levels are associated with an elevated incidence of cardiovascular pathologies, and are both diagnostic of disease, and prognostic of poor outcomes (e.g. Ref. \[[@bib44], [@bib45], [@bib46], [@bib47]\]). MPO may accumulate in the sub-endothelial space of the artery wall as a result of extracellular release from leukocytes as a consequence of inappropriate cellular processing, phagolysosomal leakage, and cell damage/death (e.g. NETosis or necrosis), or as a result of ingress from plasma, as MPO undergoes rapid transcytosis through endothelial cells \[[@bib25],[@bib48],[@bib49]\]. MPO binds to extracellular materials including low- and high-density lipoproteins \[[@bib50], [@bib51], [@bib52], [@bib53]\], glycosaminoglycans, proteins, proteoglycans and glycoproteins of the ECM \[[@bib19],[@bib23],[@bib25],[@bib54], [@bib55], [@bib56]\], via ionic interactions, resulting from the cationic nature of MPO (pI 9.2). The bound MPO appears (at least in some cases) to be catalytically-active \[[@bib19]\], and capable of inducing the formation of di-Tyr \[[@bib57],[@bib58]\], carbonyl compounds \[[@bib19],[@bib59]\], and biological dysfunction \[[@bib17],[@bib19],[@bib23],[@bib60]\]. High levels of fibronectin are present in human atherosclerotic lesions \[[@bib26],[@bib27]\], and co-localization of MPO, HOCl-modified proteins, and macrophages has been observed in atherosclerotic lesions \[[@bib61]\]. The accumulation of fibronectin during atherogenesis may drive MPO accumulation, and contribute to MPO-mediated damage in the growing lesion, as HOCl would be expected to react with nearby species due to its high reactivity with proteins \[[@bib62], [@bib63], [@bib64]\] and limited diffusion radius \[[@bib65]\]. Thus, both fibronectin and MPO have been reported to be targets of HOCl \[[@bib17]\]. Previous MS studies have mapped the type and extent of these modifications \[[@bib16],[@bib17]\]. Interestingly, the extent of MPO binding appears to increase with higher levels of fibronectin modification \[[@bib19]\], consistent with a vicious cycle of binding, catalytic activity, fibronectin damage and further MPO binding \[[@bib19]\].

Analysis of the effects of MPO/H~2~O~2~/Cl^−^ system on human plasma fibronectin indicate that aggregate formation occurs with low (100x) molar ratios of H~2~O~2~ ([Fig. 2](#fig2){ref-type="fig"}). This was observed under both reducing and non-reducing conditions, with higher levels detected in the latter case, consistent with both reducible (probably disulfide) and non-reducible crosslinks. This behavior is similar to that of reagent HOCl under identical conditions \[[@bib16]\]. The reducible aggregates are therefore ascribed to HOCl reactions, rather than inter-protein electron transfer processes \[[@bib66]\], or MPO-derived radicals \[[@bib67]\]. A plausible mechanism involves conversion of Cys residues, by HOCl \[[@bib68]\], to sulfenic acids (RSOH) that then react with another thiol to form a disulfide \[[@bib69]\]. This may occur intra-, or inter-molecularly to give reducible cross-linked species \[[@bib70]\]. This mechanism is supported by the known consumption of Cys residues on fibronectin by reagent HOCl \[[@bib16]\]. The non-reducible cross-links ([Fig. 2](#fig2){ref-type="fig"}) may involve inter-molecular di-Tyr, di-Trp, Trp-Tyr, or other linkages which contain strong covalent bonds \[[@bib71]\], formed by radical-radical dimerization (e.g. of two Tyr phenoxyl radicals, two Trp-indolyl radicals, or cross-reactions of these species \[[@bib71],[@bib72]\]). Di-Tyr has been reported on fibronectin exposed to an MPO system, and in greater quantities than with reagent HOCl \[[@bib59]\]. These data implicate radical intermediates, possibly generated by electron transfer from fibronectin to Compound I or II of MPO (cf. data for other heme proteins and peroxidases \[[@bib66],[@bib67],[@bib73]\]).

The fibronectin fragmentation detected with MPO/H~2~O~2~/Cl^−^ ([Fig. 2](#fig2){ref-type="fig"}) is similar to that detected with reagent HOCl \[[@bib16]\], and increased with higher concentrations of H~2~O~2~. This fragmentation may arise via (non-radical) chloramine/chloramide formation and subsequent hydrolysis reactions to give carbonyls \[[@bib74], [@bib75], [@bib76]\], or via nitrogen-centred radicals formed on chloramine/chloramide decomposition; both processes are known to result in protein fragmentation \[[@bib74],[@bib75]\].

Apparent shifts in molecular mass were observed for fibronectin exposed to MPO/H~2~O~2~/Cl^−^ ([Fig. 2](#fig2){ref-type="fig"}). These only occurred in the presence of H~2~O~2~, and hence are not a result of direct MPO binding, and therefore are likely to arise from oxidant-induced reactions. HOCl can modify specific protein side chains, resulting in unfolding or altered protein conformations, that migrate differently on gels, and thereby appear to have an altered molecular mass \[[@bib16],[@bib77]\]. Oxidation can also increase the molecular mass of proteins as a result of (multiple) oxygen or chlorine atom incorporation \[[@bib78]\], but the apparent mass changes are large, and hence unlikely to arise from this mechanism. Further investigations are needed to define the origin of these changes, which may be highly heterogenous.

The differences observed between the low (0.02 μM) and high MPO (0.1 μM) concentrations in the MPO/H~2~O~2~/Cl^−^ system (cf. [Fig. 2](#fig2){ref-type="fig"}, [Fig. 3](#fig3){ref-type="fig"}A and B), is consistent with MPO binding to fibronectin (as reported previously \[[@bib19]\]), with more marked alterations seen with stoichiometric concentrations, than when the MPO is at higher concentrations. This may be due to binding of excess MPO to other fibronectin sites, or the presence of unbound MPO which generates oxidants in free solution, and leads to untargeted protein damage.

HOSCN is a major alternative oxidant generated by the MPO system when SCN^−^ is present in the absence of Cl^−^, or when concentrations of SCN^−^ are towards the higher end of the concentrations detected physiologically in humans (see earlier) in the presence of Cl^−^. Treatment of fibronectin with MPO/SCN^−^ and increasing amounts of H~2~O~2~ ([Fig. 3](#fig3){ref-type="fig"}) resulted in structural modifications similar to those observed with reagent HOSCN \[[@bib16]\]. As HOSCN has a high specificity for thiols \[[@bib31]\], these aggregates are likely to be disulfide-linked species, formed from the limited number of Cys residues in fibronectin, or from oxidant-catalyzed thiol-disulfide exchange \[[@bib79]\]. This conclusion is supported by the Cys depletion observed with reagent HOSCN \[[@bib16]\], which is greater than that observed with HOCl. The apparent changes in fibronectin molecular mass is likely to arise, in this case, from modified protein conformers, rather than backbone cleavage, as there are limited data for HOSCN-induced fragmentation \[[@bib31],[@bib80]\].

Localized damage induced by MPO/H~2~O~2~ arising from MPO bound to fibronectin, may explain the epitope changes observed in the presence of Cl^−^ or SCN^−^. However, as a complete 3-D structure of fibronectin is not available, and putative MPO binding site(s) are unknown, the modification data available for HOCl and MPO/H~2~O~2~/Cl^−^ cannot be fully interpreted \[[@bib17]\]. However, despite this, the *consequences* are relatively clear. Fibronectin typically promotes endothelial cell proliferation \[[@bib81], [@bib82], [@bib83], [@bib84]\], probably via multiple mechanisms, including cell shape modulation, interactions involving cell-surface integrins, PI3 kinase and NF-kappa B pathways, and mTOR signaling \[[@bib81], [@bib82], [@bib83], [@bib84]\]. However, modification of fibronectin by MPO/H~2~O~2~/Cl^−^ results in decreased adhesion and 'rounding up' of human umbilical vein \[[@bib22]\] and bovine aortic endothelial cells \[[@bib23]\]. In the latter case, this has been attributed to an inability of cells to bind to modified ECM via an F-actin mediated adhesion pathway \[[@bib23]\]. The data presented here (and also previously with reagent HOCl \[[@bib16]\]), indicate that adhesion and metabolic activity of primary HCAEC are impaired when fibronectin is modified prior to HCAEC addition. The experimental design employed here does not involve any direct oxidant exposure of the cells, and therefore indicates that the protein modifications are causal in these changes. The reduction in CBF and HBF recognition that are important for cell binding ([Fig. 1](#fig1){ref-type="fig"}, [Fig. 3](#fig3){ref-type="fig"}) are consistent with this loss of adhesion ([Fig. 5](#fig5){ref-type="fig"}), as is the increased recognition of fibronectin by mAb 2D10G9, which is indicative of HOCl-mediated damage. In contrast, the MPO/H~2~O~2~/SCN^−^ system induced only modest CBF changes, with these being less severe than with reagent HOCl and HOSCN \[[@bib16]\], and also MPO-derived HOCl. Both reagent HOSCN \[[@bib16]\] and MPO-derived HOSCN ([Fig. 3](#fig3){ref-type="fig"}) had little effect on the HBF epitope. Consistent with these data, no changes were detected in HCAEC cell adhesion and metabolic activity.

The Cl^−^ and SCN^−^ concentrations present *in vivo* determine the relative concentrations of HOCl and HOSCN generated by MPO. HOCl can also react directly with SCN^−^ (*k* 2.3 × 10^7^ M^−1^ s^−1^ \[[@bib85]\]) further diminishing HOCl, and enhancing HOSCN, levels. Consistent with these data, increasing concentrations of SCN^−^ modulated the effects of the MPO/H~2~O~2~/Cl^−^ system, with 20 μM SCN^−^ giving a complete reversal of the loss of CBF and HBF recognition, as detected by ELISA, and disappearance of the HOCl-generated epitopes recognized by 2D10G9 ([Fig. 1](#fig1){ref-type="fig"}). This suggests that these conditions minimize HOCl formation.

In contrast to the ELISA data, some limited modifications were detected with high concentrations of SCN^−^ on the SDS-PAGE gels and immunoblots, though concentrations \>100 μM did decrease fragmentation and aggregation. The differences between the ELISA and SDS-PAGE data are likely to be due to the higher H~2~O~2~ concentrations used for the experiments (though the SCN^−^: H~2~O~2~ *ratio* was kept constant) and hence a greater oxidant flux. The modifications detected with the highest concentrations of SCN^−^, suggest that MPO-derived HOSCN can induce modifications, probably at Cys residues, but these do not impact on the CBF or HBF domains significantly (cf. the ELISA data). Thus, HOSCN does appear to modify fibronectin to a limited extent, but in a different manner to HOCl or MPO/H~2~O~2~/Cl^−^.

Overall, the data presented here support the hypothesis that MPO, in the presence of H~2~O~2~ and Cl^−^ or SCN^−^, generates HOCl and HOSCN (respectively), and also radicals, that modify fibronectin by different mechanisms. Cl^−^ and SCN^−^ appear to compete for reaction with Compound I of MPO, with increasing concentrations of SCN^−^ decreasing: a) HOCl generation; b) the extent of functionally-important (but not all) modifications on fibronectin; and c) the loss in endothelial cell adhesion and metabolic activity. The enzyme system with both anions present, is likely to mimic the situation *in vivo* more closely than the reagent oxidants, or either enzyme system *per se*. Furthermore, interactions between MPO and fibronectin appear to modulate both the sites and severity of damage, with the modifications induced by stoichiometric (or less) MPO, relative to fibronectin, showing greater differences to the reagent oxidant, than the high MPO system, consistent with MPO binding directing damage to particular sites. These sub-stoichiometric or stoichiometric systems are most likely to be of biological relevance. Enhancing SCN^−^ levels at *in vivo* sites of inflammation, where MPO induces tissue damage, should induce a switchover from HOCl to HOSCN formation, limit tissue modification and be of potential therapeutic value, as suggested by *in vitro* and *in vivo* studies \[[@bib35], [@bib36], [@bib37],[@bib39]\].
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